Knobbe Martens
Ben Harris has a diverse range of work experience in the field of communications and public relations. Ben is currently serving as the Director of Communications and Public Relations at Knobbe Martens. Prior to their current role, they worked as a PR and Communications Professional for an undisclosed company.
From 2011 to 2022, Ben held various positions at Akin Gump Strauss Hauer & Feld LLP, including Director of Communications and Communications Manager. In these roles, they were responsible for overseeing global communications and public relations efforts for the law firm, managing media relations, developing talking points, coaching lawyers on media interviews, and overseeing social media content.
Prior to their time at Akin Gump, Ben worked as a Marketing Communications Manager at Venable LLP from 2007 to 2011. In this position, they oversaw client-facing communications, provided editorial direction, and developed social media strategies.
Ben also served as a Board member for the Legal Marketing Association from 2006 to 2010, where they contributed to the organization's strategic planning and initiatives.
Earlier in their career, Ben worked as a Marketing Manager at Lerch, Early & Brewer from 2004 to 2007, where they managed marketing communications, business development activities, event planning, media relations, and the redesign of the firm's website.
Ben began their career as a Marketing Manager at The Law Firm of Shihab & Associates, Co., LPA from 2001 to 2004, where they led client outreach efforts, managed communications, developed the firm's first client database, and participated in tradeshows and events.
Ben Harris has a wealth of experience in communications and public relations within the legal industry, with a strong focus on media relations, content creation, and strategic communications planning.
Ben Harris attended The Ohio State University Fisher College of Business from 1995 to 2000. Ben obtained a Bachelor of Science in Business Administration (BSBA) with a specialization in Marketing.
This person is not in any teams
This person is not in any offices
Knobbe Martens
2 followers
Our firm boasts IP law’s largest and most experienced biotechnology group, with more than 60 attorneys and scientists representing clients in all stages of their business and technology development. Our clients are innovators in a variety of disciplines including PCR, molecular tools and probes, immunology (antibodies and other binding proteins), cell varieties and uses (including stem cells) and biological polymers, to name but a few. Our expertise across the entire biotech landscape gives us great insight into specific technologies, systems and markets. More importantly, our holistic understanding of the interrelated technologies and systems typically involved in a single invention allows us to provide coordinated guidance and counsel from inception though introduction. Working in collaboration with more than 300 IP firms worldwide, we effect patent, trademark, copyright, and other filings, and direct oppositions, cancellations, and litigation matters in over 120 countries. We have considerable experience in negotiating and drafting traditional licensing agreements as well as agreements for strategic alliances, partnerships and joint ventures. We also maintain a talented litigation department adept in all aspects of biotechnology IP law, including the Biosimilars legislation. Our extensive Hatch-Waxman litigation experience combined with our understanding of the biotechnology industry uniquely positions Knobbe Martens to help clients develop and implement litigation strategies designed to maximize their place in the Biosimilars market place. In addition, we have considerable experience litigating before the U.S. Court of Appeals for the Federal Circuit and the International Trade Commission. Our attorneys have experience in all areas of Biotechnology, including: Aesthetic & Cosmetic Biotechnology Antibodies & Immunology Biofuels Biological Manufacturing Of Chemicals Biologics Diagnostic Tools Genomics Industrial Enzymes Peptides Personalized Medicine Research Tools & Reagents Stem Cells & Regenerative Medicine Synthetic Biology & Nanotechnology Therapeutics Tissue Engineering Transgenic Animals Vaccines